218 related articles for article (PubMed ID: 33519787)
21. Treatment of severe
Zweijpfenning SMH; Kops SEP; Boeree MJ; Kuipers S; van Ingen J; Hoefsloot W; Magis-Escurra C
ERJ Open Res; 2021 Oct; 7(4):. PubMed ID: 34820449
[No Abstract] [Full Text] [Related]
22. In vitro, in vivo, and intracellular chemotherapeutic activity of B746, a clofazimine analogue against Mycobacterium avium complex.
Gangadharam PR; Ashtekar D; O'Sullivan JF
Tuber Lung Dis; 1992 Aug; 73(4):192-9. PubMed ID: 1477384
[TBL] [Abstract][Full Text] [Related]
23. Role of Clofazimine in Treatment of
Nasiri MJ; Calcagno T; Hosseini SS; Hematian A; Nojookambari NY; Karimi-Yazdi M; Mirsaeidi M
Front Med (Lausanne); 2021; 8():638306. PubMed ID: 33968952
[No Abstract] [Full Text] [Related]
24. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
Ramirez J; Mason C; Ali J; Lopez FA
J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
[TBL] [Abstract][Full Text] [Related]
25. [Non-tuberculous mycobacteriosis. What has been coming out].
Kajiki A
Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655
[TBL] [Abstract][Full Text] [Related]
26. Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages.
Rastogi N; Labrousse V; Bryskier A
Antimicrob Agents Chemother; 1995 Apr; 39(4):976-8. PubMed ID: 7786006
[TBL] [Abstract][Full Text] [Related]
27. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.
Bermudez LE; Kolonoski P; Wu M; Aralar PA; Inderlied CB; Young LS
Antimicrob Agents Chemother; 1999 Aug; 43(8):1870-4. PubMed ID: 10428905
[TBL] [Abstract][Full Text] [Related]
28. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Jul; 66(7):489-92. PubMed ID: 1890791
[TBL] [Abstract][Full Text] [Related]
29. [Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
Ogawa K; Sano C
Kekkaku; 2013 Mar; 88(3):355-71. PubMed ID: 23672176
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S
Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory
Kim BG; Kim H; Kwon OJ; Huh HJ; Lee NY; Baek SY; Sohn I; Jhun BW
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32937940
[TBL] [Abstract][Full Text] [Related]
32. Human mesenchymal stromal cells inhibit
Shaw TD; Krasnodembskaya AD; Schroeder GN; Doherty DF; Silva JD; Tandel SM; Su Y; Butler D; Ingram RJ; O'Kane CM
Thorax; 2024 Mar; ():. PubMed ID: 38508718
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
Sato K; Akaki T; Tomioka H
J Antimicrob Chemother; 1998 Jan; 41(1):77-83. PubMed ID: 9511040
[TBL] [Abstract][Full Text] [Related]
34. Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy.
Ito Y; Miwa S; Shirai M; Kanai M; Fujita K; Ohba H; Iwaizumi E; Oshima T; Kojima S; Suda T; Hayakawa H
Respir Med; 2020 Aug; 169():106025. PubMed ID: 32442113
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.
Kansal RG; Gomez-Flores R; Sinha I; Mehta RT
Antimicrob Agents Chemother; 1997 Jan; 41(1):17-23. PubMed ID: 8980748
[TBL] [Abstract][Full Text] [Related]
36. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM
N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931
[TBL] [Abstract][Full Text] [Related]
37. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
Kawahara S; Nagare H
Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
[TBL] [Abstract][Full Text] [Related]
38. Risk-benefit assessment of therapies for Mycobacterium avium complex infections.
Griffith DE
Drug Saf; 1999 Aug; 21(2):137-52. PubMed ID: 10456381
[TBL] [Abstract][Full Text] [Related]
39. Treatment of
Kwon YS; Koh WJ; Daley CL
Tuberc Respir Dis (Seoul); 2019 Jan; 82(1):15-26. PubMed ID: 30574687
[TBL] [Abstract][Full Text] [Related]
40. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
Research Committee of the British Thoracic Society
Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
